IVR联合PDT治疗湿性年龄相关性黄斑变性的临床观察

doi:10.6040/j.issn.1673-3770.0.2016.227

摘要/Abstract

摘要： 目的观察雷珠单抗联合光动力疗法治疗湿性年龄相关性黄斑变性(wAMD)的长期有效性及安全性。方法回顾分析wAMD患者11例(11眼),均在初始接受了玻璃体腔注射雷珠单抗0.5 mg后7 d内联合标准剂量的光动力疗法(PDT),并根据患者复诊情况行玻璃体腔注射雷珠单抗(IVR)再治疗或者观察。统计患者最佳矫正视力(BCVA)、中心视网膜厚度(CRT)、眼压(IOP)及IVR再治疗次数。结果治疗后第2、3、6个月患者BCVA较治疗前提高(P<0.05);治疗后第18个月患者BCVA较治疗前平均提高了(7.31±15.00)个字母,CRT较治疗前下降(P<0.05);IOP治疗前后无统计学差异;前18个月患者IVR再治疗平均次数为1.55次(0~8次)。结论 IVR联合PDT可降低wAMD临床干预次数并延长疗效。

关键词: 血管内皮生长因子, 光动力疗法, 湿性年龄相关性黄斑变性, 联合疗法

Abstract: Objective To investigate the potential long-term benefit of combination of intravitreal ranibizumab with photodynamic therapy for the treatment for wet age-related macular degeneration(wAMD). Methods A retrospective review was conducted on 11 eyes of 11 patients that received intravitreal ranibizumab(IVR)0.5 mg combined with standard photodynamic therapy(PDT)within 7 days, and thereafter retreatment as required with intravitreal ranibizumab monotherapy for at least 18 months. Collected data included: best-corrected visual acuity(BCVA), central retinal thickness(CRT), intraocular pressure(IOP)and number of retreatment. Results The mean BCVA was apparently improved from baseline at the 2nd, 3rd and 6th month of follow-up compared to baseline(P<0.05, showing improvement of 7.31±15.00 letters from baseline at eighteen months of follow-up. )Meanwhile, CRT decreased significantly compared with pre-treatment(P<0.05). During the treatment, IOP kept steady with no statistical difference between pre- and post-treatment.The study eyes received an average of 1.55 times(range: 0 to 8)of intravitreal anti-VEGF reagent injection during the total 18 months period after initial combination therapy. Conclusion Combination therapy could reduce times of intravitreal anit-VEGF reagent injection and maintaine long-lasting effect on wAMD.

Key words: Wet age-related macular degeneration, Vascular endothelial growth factor, Photodynamic therapy, Combination therapy

中图分类号:

R774

王翠,颜昕,赵博军. IVR联合PDT治疗湿性年龄相关性黄斑变性的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 94-97.

WANG Cui, YAN Xin, ZHAO Bojun. Combination of intravitreal ranibizumab with photodynamic therapy in the treatment of wet age-related macular degeneration.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 94-97.

参考文献

[1] Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents[J]. Ophthalmology, 2001, 108(4):697-704.
[2] Wong CW, Yanagi Y, Lee WK, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians[J]. Prog Retin Eye Res, 2016, 53:107-139.
[3] 葛坚,何明光,赵家良,等. 我国九省眼病调查中广东省阳西县50岁及以上人群盲和中、重度视力损伤患病率及致病原因调查[J]. 中华眼科杂志,2014,50(3):167-172. GE Jian, HE Mingguang, ZHAO Jialiang, et al. Prevalence of blindness and moderate and severe visual impairment among adults aged 50 years or above in Yangxi county of Guangdong province: the china nine-province survey[J]. Chin J Ophthalmol, 2014, 50(3):167-172.
[4] 阴正勤,赵家良,李平华,等. 我国九省眼病调查中重庆市永川区50岁及以上人群盲和中、重度视力损伤患病率及致病原因调查[J]. 中华眼科杂志,2013,49(9):777-782. YIN Zhengqin, ZHAO Jialiang, LI Pinghua, et al. Prevalence and causes of blindness and moderate and severe visual impairment among adults aged 50 years or above in Yongchuan district of Chongqing city: the china nine-province survey[J]. Chin J Ophthalmol, 2013, 49(9):777-782.
[5] 吕建华,赵家良,Leon B.Ellwein,等. 我国九省眼病调查中河北省隆尧县50岁及以上人群盲和中、重度视力损伤患病率及致病原因调查[J]. 中华眼科杂志,2013,49(9):783-788. LV Jianhua, ZHAO Jialiang, Ellwein LB, et al. Prevalence and causes of blindness and moderate and severe visual impairment among adults aged 50 years or above in Longyao county of Hebei province: the china nine-province survey[J]. Chin J Ophthalmol, 2013, 49(9):783-788.
[6] Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis[J]. Lancet Glob Health, 2014, 2(2):106-116.
[7] Ferris FR, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy[J]. Arch Ophthalmol, 1984, 102(11):1640-1642.
[8] Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2[J]. Arch Ophthalmol, 2001, 119(2):198-207.
[9] Krebs I, Vecsei MV, Bodenstorfer J, et al. Comparison of ranibizumab monotherapy versus combination of ranibizumab with photodynamic therapy with neovascular age-related macular degeneration[J]. Acta Ophthalmol, 2013, 91(3):e178-e183.
[10] Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results[J]. Ophthalmology, 2012, 119(5):992-1000.
[11] Holladay JT. Visual acuity measurements[J]. J Cataract Refract Surg, 2004, 30(2):287-290.
[12] Tsuchihashi T, Mori K, Ueyama K, et al. Five-year results of photodynamic therapy with verteporfin for Japanese patients with neovascular age-related macular degeneration[J]. Clin Ophthalmol, 2013, 7:615-620.
[13] Stewart MW. individualized treatment of neovascular age-related macular degeneration: what are patients gaining or losing[J]. J Clin Med, 2015, 4(5):1079-1101.
[14] Si JK, Tang K, Bi HS, et al. Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials[J]. Int J Ophthalmol, 2014, 7(3):541-549.
[15] Chew EY, Clemons TE, Bressler SB, et al. Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye(HOME)study[J]. Ophthalmology, 2014, 121(2):535-544.
[16] Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor(VEGF), VEGF receptor 3, and pigment epithelium-derived factor[J]. Invest Ophthalmol Vis Sci, 2003, 44(10):4473-4480.
[17] Simader C, Ritter M, Bolz M, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration[J]. Ophthalmology, 2014, 121(6):1237-1245.
[18] Zhang S, An N, Ha W, et al. Factors correlated with the resolution of macular oedema after one dose injection of intravitreal triamcinolone acetonide treatment in branch retinal vein occlusion[J]. J Int Med Res, 2016, 44(3):685-697.

相关文章 15

[1]	朱明琼,李征,刘茹,田涛,彭婧利,吕倩怡,谭华霞. 基于OCT/OCTA的AI筛查系统在抗VEGF治疗糖尿病性黄斑水肿患者效果评价中的应用[J]. 山东大学耳鼻喉眼学报, 2026, 40(1): 68-73.
[2]	王丽雪,曾毅,王丽欣,彭先兵. 浸润毕罗芬明胶海绵在功能性鼻内镜鼻窦手术后应用效果的临床观察[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 16-25.
[3]	徐恩沛,孙先勇. 渗出性年龄相关性黄斑变性并发视网膜色素上皮脱离的诊治进展[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 125-142.
[4]	王露萍,寇芳柠,王皓,张灿伟,王艳玲,尤冉,吴伟珍. 视网膜下高反射物质在抗VEGF治疗nAMD患者中对视力预后的影响[J]. 山东大学耳鼻喉眼学报, 2022, 36(6): 101-105.
[5]	刘乐乐,孔香云综述申家泉审校. 睫状体分泌功能减弱性手术在青光眼治疗中的进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(6): 123-128.
[6]	李曼冯雪,王艳玲. 眼缺血综合征与缺血性脑卒中相关性研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(5): 88-92.
[7]	樊慧娟，张海利. HIF-1α与VEGF在中耳胆脂瘤中的研究进展[J]. 山东大学耳鼻喉眼学报, 2021, 35(5): 93-97.
[8]	刘志高,王淑雅,韩旭光,王玉,李志伟,马爱华,赵博军. 增殖性糖尿病视网膜病变术前玻璃体腔应用阿柏西普的时机及其疗效观察[J]. 山东大学耳鼻喉眼学报, 2021, 35(1): 99-103.
[9]	李萱, 黄映湘. 25例虹膜新生血管发生原因探讨[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 41-47.
[10]	郭欣璐, 高健生, 接传红. 中医药联合激光及手术治疗眼缺血综合征一例并文献复习[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 48-52.
[11]	李浩,李延忠,王岩. HIF-1α、VEGF在阻塞性睡眠呼吸暂停低通气综合征患者[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 43-47.
[12]	周玮琰,王洪亚,杜秀娟,董卫红. 甘糖酯对糖尿病大鼠视网膜病变中血管生成因子VEGF表达的影响[J]. 山东大学耳鼻喉眼学报, 2017, 31(2): 90-95.
[13]	赵露,谢国丽,王艳玲. 玻璃体腔注射雷珠单抗对湿性年龄相关性黄斑变性患者眼血流动力学的影响[J]. 山东大学耳鼻喉眼学报, 2016, 30(4): 101-104.
[14]	李盈盈, 周涵, 张伟强, 董伟达. 沉默HIF-1α基因对鼻黏膜上皮细胞生长因子表达的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(5): 38-42.
[15]	李俊英. 瑞舒伐他汀联合非诺贝特对老年糖尿病视网膜病变患者血管内皮功能的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(5): 72-75.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed